Breadcrumb

[A14-11] Addendum to Commission A13-44 (ipilimumab, new therapeutic indication)

Overview

Overview

Commission: Commission awarded on 2014-03-11 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Addendum to Commission A13-44 (ipilimumab, new therapeutic indication)  [PDF, 135 kB]Further documents
Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Contact address:to the contact form
Linked projects: [A14-15] Second Addendum to Commission A13-44 (ipilimumab, new therapeutic indication)
Status: Commission completed

[A13-44] Ipilimumab (new therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2014-06-05 Addendum to Commission A13-44 (ipilimumab, new therapeutic indication) 135 kBPDFdownload file

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.


At a glance


Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close